Advances in mutation testing for molecular-targeted
cancer therapies have led to the increased use of archived
formalin-fixed
paraffin-embedded (FFPE)
tumors. However,
DNA extracted from FFPE
tumors (FFPE
DNA) is problematic for mutation testing, especially for amplicon-based massively parallel sequencing (MPS), owing to DNA fragmentation and artificial C:G > T:A single
nucleotide variants (SNVs) caused by deamination of
cytosine to
uracil. Therefore, to reduce artificial C:G > T:A SNVs in amplicon-based MPS using FFPE
DNA, we evaluated the efficacy of
uracil DNA glycosylase (UDG) pretreatment, which can eliminate
uracil-containing
DNA molecules, with 126 archived FFPE
esophageal cancer specimens. We also examined the association between the frequency of C:G > T:A SNVs and
DNA quality, as assessed by a quantitative PCR (qPCR)-based assay. UDG pretreatment significantly lowered the frequency of C:G > T:A SNVs in highly fragmented
DNA (by approximately 60%). This effect was not observed for good- to moderate-quality
DNA, suggesting that a predictive assay (i.e.,
DNA quality assessment) needs to be performed prior to UDG pretreatment. These results suggest that UDG pretreatment is efficacious for mutation testing by amplicon-based MPS with fragmented
DNA from FFPE samples.